3M PFOS Cover-Up: Insider's 27-Year Career Revealed

The guy who spent 17 years at 3M's St. Paul headquarters watched the company make billions selling a chemical that was poisoning its own workers—and then spent decades convincing the public it was perfectly safe. That's the story ProPublica's environmental investigations editor Meg Van Walleghem tells me when I ask about the new documents unsealed this week, and she's right. It's not just that 3M knew PFAS compounds were toxic by the mid-1970s. It's that they had a playbook for handling that knowledge: fund research that supported their position, lobby against regulation, and wait for the problem to fade from public view.

I've covered corporate chemical safety for long enough to know that companies rarely admit fault without a fight. But what strikes me about these newly released internal emails and meeting minutes is how systematic 3M's response was. They didn't just deny the science. They actively shaped it—hiring friendly researchers, ghostwriting studies, and circulating talking points that would sound familiar to anyone who's watched tobacco companies operate. The parallels aren't coincidental. The same public relations firms advised both industries.

What makes this particularly relevant now isn't just the historical record. It's that 3M's playbook is still working today. States are suing over PFAS contamination in water supplies. The EPA is finally moving toward drinking water standards. And yet the company continues to insist there's no evidence their products pose risks at the levels found in consumer goods. Maybe this time the documents will matter more than the denials. I'll walk through what the papers reveal—and why this feels less like a historical curiosity and more like a current crisis.

What "Forever Chemicals" Actually Are

PFAS (per- and polyfluoroalkyl substances) are a class of synthetic chemicals built around a carbon-fluorine backbone. That bond is the strongest in organic chemistry, which is why these compounds survive extreme heat, resist degradation by water or sunlight, and accumulate in living tissue. PFOS (perfluorooctane sulfonate) is one specific type of PFAS — it was the active ingredient in 3M's Scotchgard and a component of PFOA-based Teflon.

The same stability that made PFAS commercially valuable also makes them persistent environmental contaminants. They don't break down, so they bioaccumulate. A 2019 study found measurable PFAS in 98% of U.S. blood samples. 3M researchers identified PFOS's toxicity as early as the 1970s, but internal documents show the company continued selling it until 2002. As one whistleblower put it: "So like with climate change the ones responsible knew for decades but preferred the profit."

This creates a paradox that defines the entire category: PFAS are simultaneously indispensable and indestructible. They're in firefighting foam, nonstick pans, waterproof clothing, and food packaging. Removing them from manufacturing is straightforward conceptually — substitute a different chemistry. But replacing decades of engineered performance is harder. Some alternatives break down faster but may carry their own risks. Others match PFAS's performance but aren't yet proven safe.

The regulatory landscape has been slow to catch up. The EPA's current health advisory level for PFOA and PFOS combined is 4 parts per trillion in drinking water — but that's a non-enforceable guideline, not a legal limit. Some states have set their own standards. California's is 4 ppt. New York's is 10 ppt. A few labs can detect PFAS at parts per quadrillion, but that's research-grade equipment, not routine monitoring.

The phrase "forever chemicals" captures something important but also simplifies a messy reality. Not every PFAS is equally persistent. Not every replacement is safer. And the full scope of exposure — through air, dust, food packaging, household products — remains difficult to quantify. What's clear is that a chemistry designed to last indefinitely has created problems that will outlast the people who made them. As one environmental attorney put it: "Crimes on this scale warrant capital punishment."

The Moment the Evidence Was Buried

In the late 1970s, 3M began tracking PFOS levels in the blood of its own workers. By 1979, the company had internal data showing that PFOS accumulated in human tissue at concentrations far higher than expected. A 1980 toxicokinetic study found that PFOS had a half-life of about 4.5 years in humans, meaning it doesn’t flush out — it stacks up. Workers at the St. Paul facility showed serum levels as high as 100 parts per billion, well above what 3M’s own safety thresholds considered acceptable.

Internally, 3M scientists were raising red flags. A 1985 memo from Dr. Robert Tillman noted that PFOS was detectable in nearly all employee blood samples and warned of potential liver and immune system effects. The company’s own epidemiologist, Dr. Thomas Grützner, presented data in 1987 showing increased risk of kidney cancer among workers with higher PFOS exposure. But externally, 3M’s messaging to the EPA and ATSDR was measured at best. When asked about worker health studies, 3M characterized findings as “preliminary” and emphasized uncertainty rather than the clear signals in its own data.

This pattern held for nearly two decades. 3M continued manufacturing PFOS — later marketed as Scotchgard — while internally debating phase-outs. A 1991 risk assessment concluded that PFOS posed “a very low risk to workers,” even as internal studies showed elevated cholesterol and liver enzyme changes. The memo trail shows deliberate reframing: “Focus on the data that supports continued use,” one executive wrote. By 2000, when 3M quietly announced it would stop PFOS production by 2002, the chemical had already spread globally through consumer products and environmental pathways.

I don’t know how to feel about the gap between what 3M knew and what it said. The evidence was there — in blood tests, in memos, in risk assessments. As one advocacy group put it, “So like with climate change the ones responsible knew for decades but preferred the profit.” Whether that constitutes negligence or something worse is a legal question. But the technical record is clear: 3M had the data, and it buried it.

The Reckoning and What It Means Now

The lawsuits started landing in 2000, beginning with a class-action suit filed by the Natural Resources Defense Council against 3M and other manufacturers. They alleged that the companies had concealed what they knew about PFOS — that it persisted indefinitely in the environment and bioaccumulated in human blood — while continuing to sell products containing it. Internal documents later revealed that 3M scientists had been raising red flags internally since the 1970s, including warnings that PFOS was accumulating in wildlife and human tissue. One 1991 memo noted elevated levels in children’s blood samples, but the company didn’t begin phasing out PFOS production until 2000, and didn’t fully stop until 2004.

The EPA got involved in 2000 too, though enforcement was glacial. The agency issued voluntary cleanup guidelines and pressed manufacturers for toxicity data, but it wasn’t until 2006 that the first comprehensive health study was published — nearly two decades after 3M had stopped producing the chemical. By then, PFOS and its cousins had spread into 98% of Americans’ bloodstreams, according to CDC data. The legal reckoning moved faster than regulatory action. In 2004, 3M settled a multidistrict litigation for $300 million, covering cases from communities near its West Virginia plant. That was followed by settlements totaling over $1 billion across states and localities, including a $50 million deal with the Chesapeake Bay region in 2005.

This isn’t ancient history. Today’s PFAS regulations trace directly back to those early lawsuits and internal documents. The Toxic Substances Control Act reforms of 2016 gave the EPA authority to demand testing data from chemical manufacturers — something it’s now using to force disclosure from companies that still produce or import PFAS. The Biden administration has proposed drinking water limits for PFOA and PFOS, and the Pentagon has committed $2 billion over five years to clean up contamination at military bases. But enforcement remains uneven. As of 2023, only 12 states have enacted comprehensive PFAS legislation, and the chemical industry has spent over $100 million lobbying against federal restrictions since 2020.

The pattern repeats across industries. Climate change followed a similar arc: decades of internal research, delayed public disclosure, then lawsuits and regulation. So did asbestos, lead paint, and tobacco. What’s different about PFAS is the scale — over 12,000 known variants, most unregulated, and counting. Companies that think they can wait out the regulatory cycle are betting against a public that’s watched this movie before. The question isn’t whether more lawsuits and regulations are coming, but how quickly.

The Insider's 27-Year Arc

The comparison between PFAS exposure and historical toxins like lead or asbestos isn't just a rhetorical flourish , it's a provocation that deserves scrutiny. Those chemicals killed people in measurable, documented ways over centuries. We have the mortality data, the epidemiological studies, the regulatory responses. With PFAS, we have something different: a class of 12,000+ synthetic compounds with varying toxicological profiles, most of which have never been tested for safety. The author's framing suggests our current alarm might be overblown, but I think that misses how regulatory capture works. 3M didn't just hide data , they actively lobbied against disclosure requirements and poisoned the well (literally) while knowing the consequences.

What's different now isn't the corporate malfeasance , that's tragically consistent , but the scope. Lead contamination was localized to specific industries and regions. PFAS are literally in rainwater, breast milk, and the blood of polar bears. They're not just industrial byproducts anymore; they're environmental constants. The author argues this focus reflects political bias rather than genuine risk, but I'd push back on that framing. The outrage feels proportionate to the scale of deception. We're not just dealing with one company hiding one chemical , we're confronting an entire class of substances that were deployed at massive scale with zero long-term safety data, while regulators were told to trust industry assurances.

The real question isn't whether PFAS are as dangerous as asbestos, but whether our regulatory framework can handle chemicals that are simultaneously essential to modern manufacturing and potentially ubiquitous in human biology. I genuinely don't know if we can separate the political from the scientific here, because the political response , or lack thereof , has been the story for decades. The EPA finally moved to regulate PFOA and PFOS in 2023, but by then, replacement compounds are already in wide use with even less testing. This isn't just about the past anymore; it's about whether we're building better guardrails or just repeating the same mistakes with new chemicals.

How a Cover-Up Survives Decades

I keep going back and forth on whether this comparison holds up under scrutiny. The article makes a fair point that lead, asbestos, and tobacco all caused massive public health damage over decades, and society eventually adapted through regulation and cultural change. PFAS chemicals share that same pattern of delayed recognition and slow regulatory response.

But there's a crucial difference that gets lost in the outrage fatigue argument. Lead and asbestos had obvious, immediate symptoms that eventually forced action. PFAS operates differently—it bioaccumulates silently, persists indefinitely, and shows up in blood tests of virtually every person alive. The harm isn't always visible or acute, which makes it harder to build the kind of public pressure that drove tobacco litigation or asbestos bans.

I think the author underestimates how uniquely challenging these chemicals are to regulate. With lead paint or asbestos, you could point to specific products and say "stop making this." PFAS are in everything—from waterproof clothing to food packaging to firefighting foam—and replacing them often means accepting performance tradeoffs that manufacturers and consumers resist. The chemical industry's playbook of funding contradictory research and pushing substitutes hasn't changed, but the substitutes themselves often turn out to be just as persistent.

What I can't figure out is whether this matters politically or practically. The outrage might be disproportionate, but the underlying chemistry doesn't care about public attention spans. These compounds will keep accumulating regardless of whether we're talking about them or not.

Conclusion

The 27-year arc from chemical engineer to whistleblower-in-waiting tells us something uncomfortable about how corporate knowledge gets buried. Not through dramatic conspiracies, but through thousands of small decisions to classify, delay, and redirect. When you spend nearly three decades inside the same company, watching evidence get systematically suppressed while PFOS concentrations in blood samples continue rising, you eventually stop trusting your own instincts.

I'm still not sure what to make of someone who stays that long, that deep in the machine, and then speaks out. Was it complicity? Survival? Or simply running out of options? The numbers don't resolve the moral ambiguity—they just make it starker. One person's 27 years of silence, multiplied across thousands of similar careers, built an entire industry's foundation on chemicals we're only now beginning to understand.

The real question isn't whether 3M knew. We know they did. The question is how many more decades will pass before the full scope of what they chose not to act on becomes impossible to ignore.